Galena Biopharma to Present at the 27th Annual ROTH Conference
Get Alerts GALE Hot Sheet
Join SI Premium – FREE
PORTLAND, Ore., March 3, 2015 (GLOBE NEWSWIRE) -- Galena Biopharma, Inc. (Nasdaq: GALE), a biopharmaceutical company developing and commercializing innovative, targeted oncology treatments that address major medical needs across the full spectrum of cancer care, today announced that Mark W. Schwartz, Ph.D., President and Chief Executive Officer will present a corporate update at the 27th Annual ROTH Conference. The presentation will take place on Monday, March 9, 2015 at 8:00 a.m. PT at the Ritz Carlton Hotel in Laguna Nigel, CA.
The presentation will be webcast and available on the Investors section of the Company's website at www.galenabiopharma.com.
About Galena Biopharma
Galena Biopharma, Inc. (Nasdaq: GALE) is a biopharmaceutical company developing and commercializing innovative, targeted oncology therapeutics that address major medical needs across the full spectrum of cancer care. Galena's development portfolio ranges from mid- to late-stage clinical assets, including a robust immunotherapy program led by NeuVax™ (nelipepimut-S) currently in an international, Phase 3 clinical trial. The Company's commercial drugs include Abstral® (fentanyl) Sublingual Tablets and Zuplenz® (ondansetron) Oral Soluble Film. Collectively, Galena's clinical and commercial strategy focuses on identifying and advancing therapeutic opportunities to improve cancer care, from direct treatment of the disease to the reduction of its debilitating side-effects. For more information, visit www.galenabiopharma.com.
CONTACT: Remy Bernarda SVP, Investor Relations & Corporate Communications (503) 405-8258 [email protected]Source: Galena Biopharma
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Gold Hunter Receives Final Order Approving Plan of Arrangement
- BGHL (GBP): NAV(s)
- Burning Rock Announces ADS Ratio Change
Create E-mail Alert Related Categories
Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!